Market Research Logo

EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026

EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026

SummaryCancer is a broad term for a group of diseases characterized by uncontrolled cell proliferation in any part of the body that may spread beyond the cells’ normal boundaries (WHO, 2017). Worldwide, it is estimated that around 14 million new cases of cancer are diagnosed each year, and 30-50% of those cases are preventable (WHO, 2017). Cancer is the second leading cause of death worldwide, with more than eight million deaths caused by cancer in 2015 (WHO, 2017). The etiology of cancer varies with each type; however, the most common risk factors include tobacco use, lack of physical exercise, unhealthy diet, and old age (WHO, 2017).

In 2016, there were more than 900,000 diagnosed incident cases of all cancer receiving chemotherapy treatment in men and women, ages 18 years and older, in the 7MM. Combination therapy was more common, with more than 75% of cases receiving chemotherapy in conjunction with surgery, radiation, or both. The remainder of about 24% casesreceived chemotherapy alone. Of those receiving chemotherapy, anemia and nausea and vomiting were the most common conditions resulting from the treatment. In 2016, there were more than 800,000 cases of chemotherapy-induced anemia and almost 750,000 cases of chemotherapy-induced nausea and vomiting in the 7MM.

In 2016, Spain had the highest age-standardized diagnosed incidence of all cancer in men at more than 570 cases per 100,000. Germany had the lowest age-standardized diagnosed incidence of all cancer in men at around 428 cases per 100,000.The US had an age-standardized diagnosed incidence of all cancer of about 435 cases per 100,000 in 2016. As far as womenare concerned, in 2016, the US had the highest age-standardized rate of over 400 cases per 100,000, while Japan had the lowest rate at around 325cases per 100,000. The UK had the highest age-standardized rate of around 400 cases per 100,000 out of the five European countries (5EU: France, Germany, Italy, Spain, and UK).

The report EpiCast Report: Supportive Care in Oncology - Epidemiology Forecast to 2026, provides an overview of the global and historical trends for all cancer in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases of all cancer segmented by age (beginning at 18 years and ending at 80 years and older) and sex. It also provides the proportion of all cancer cases treated with chemotherapy and the number of those cases that develop a chemotherapy-induced condition.

Furthermore, this report provides the number of diagnosed incident cases of prostate (men ages 35 years and older), breast (women ages 20 years and older), and lung cancer (men and women ages 20 years and older), and the proportion of those that metastasize to bone. Finally, the report also provides a forecast of the five-year diagnosed prevalent cases of all cancer in men and women combined (ages 18 years and older).

Scope

  • The Supportive Care in Oncology EpiCast Report provides an overview of the risk factors and global trends of supportive care in oncology in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of all cancer; five-year diagnosed prevalent cases of all cancer; diagnosed incident cases of all cancer treated with chemotherapy; diagnosed incident cases all cancer treated with chemotherapy with chemotherapy induced condition (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia); diagnosed incident cases of prostate cancer (men ages 35 years and older); diagnosed incident cases of breast cancer (women ages 20 years and older); diagnosed incident cases of lung cancer (men and women ages 20 years and older); diagnosed incident cases of prostate, breast, and lung cancer that metastasize to bone.
  • The supportive care in oncology epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buyThe Supportive Care in Oncology EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global oncology and chemotherapy treatment market.
  • Quantify patient populations in the global oncology and chemotherapy treatment market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chemotherapy induced conditions therapeutics in each of the markets covered.
  • Understand magnitude of chemotherapy induced conditions.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Supportive Care Oncology: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Global and Historical Trends
3.3 Forecast Methodology
3.3.1 Sources
3.3.2 Forecast Assumptions and Methods
3.4 Epidemiological Forecast for Supportive Care in Oncology (2016-2026)
3.4.1 Diagnosed Incident Cases of All Cancer
3.4.2 Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment
3.4.3 Diagnosed Incident Cases of Chemotherapy-Induced Conditions
3.4.4 Diagnosed Incident Cases of Prostate Cancer
3.4.5 Diagnosed Incident Cases of Prostate Cancer That Develop Bone Metastasis
3.4.6 Diagnosed Incident Cases of Breast Cancer
3.4.7 Diagnosed Incident Cases of Breast Cancer That Develop Bone Metastasis
3.4.8 Diagnosed Incident Cases of Lung Cancer
3.4.9 Diagnosed Incident Cases of Lung Cancer That Develop Bone Metastasis
3.4.10 Five-Year Diagnosed Prevalent Cases of All Cancer
3.5 Discussion
3.5.1 Epidemiological Forecast Insight
3.5.2 Limitations of Analysis
3.5.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologists
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
1.1 List of Tables
Table 1: 7MM, Diagnosed Incident Cases of All Cancer, Men and Women, Ages ≥20 Years
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages ≥18 Years
Figure 2: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages ≥18 Years
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Men, Ages ≥18 Years, 2016-2026
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Women, Ages ≥18 Years, 2016-2026
Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of All Cancer
Figure 6: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of All Cancer
Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Prostate Cancer
Figure 8: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Breast Cancer
Figure 9: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Lung Cancer
Figure 10: 7MM, Sources Used to Forecast Chemotherapy-Induced Conditions
Figure 11: 7MM, Sources Used to Forecast Bone Metastasis in Prostate, Breast, and Lung Cancer
Figure 12: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages ≥18 Years
Figure 13: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages ≥18 Years
Figure 14: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years
Figure 15: 7MM, Diagnosed Incident Cases of Prostate Cancer That Have Developed or Will Develop Bone Metastasis, Men, Ages ≥35 Years
Figure 16: 7MM, Diagnosed Incident Cases of Breast Cancer, Women, Ages ≥20 Years
Figure 17: 7MM, Diagnosed Incident Cases of Breast Cancer That Have Developed or Will Develop Bone Metastasis, Women, Ages ≥20 Years
Figure 18: 7MM, Diagnosed Incident Cases of Lung Cancer, Men and Women, Ages ≥20 Years
Figure 19: 7MM, Diagnosed Incident Cases of Lung Cancer That Have Developed or Will Develop Bone Metastasis, Men and Women, Ages ≥20 Years
Figure 20: 7MM, Five-Year Diagnosed Prevalent Cases of All Cancer, Men and Women, All Ages

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report